In addition, previous studies have shown that MN1 induces resistance to ATRA-induced differentiation and cell death [22], and that high-level expression of MN1 predicts ATRA resistance in AML patients, suggesting its future use as a biomarker for ATRA treatment [22], [47]. This evidence concerns the gene MN1 and acute myeloid leukemia.